A Phase 2 interventional study of Itepekimab (SAR440340) and Placebo in Bronchiectasis, sponsored by Sanofi. Completed at 117 sites in 20 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Bronchiectasis with a site in United States — 21 open to participants now, 23 under way, 2 of them phase 3. Bronchiectasis · United States.
Among the 65 studies in Bronchiectasis with a site in United States, this one is the 11th largest by enrollment of the 52 interventional ones that give a count, is one of 8 that started in 2024, is one of 15 in phase 2, and was the 50th registered.
404 studies on the registry are indexed under Bronchiectasis; 125 are open to participants now.
Browse Bronchiectasis studies →21 of the 65 studies in Bronchiectasis with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
UCB Biopharma SRL · Sites in United States
Ages 18–80
Indiana University · Sites in United States
Ages 18+
AstraZeneca · Sites in United States, Argentina, Australia and 22 more countries
Ages 12+
GlaxoSmithKline · Sites in United States, Argentina, China and 9 more countries
Ages 18–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 93 Bronchiectasis studies recruiting now, 50 (54%) set no upper age limit and 13 (14%) stop at 75 or younger; 12 take children under 18; 26 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
First in 1988; this study’s year is marked. 8 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 314 is above the median of 60 across 263 interventional studies indexed under Bronchiectasis.
Median enrollment 78 across the 52 interventional studies, 100 across the 13 observational. Of the 39 that completed or were terminated, 20 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 65 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 2 studies filed under Bronchiectasis — fewer than ten, so there is no comparison to draw.
8 of the studies in Bronchiectasis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06872892Phase 3Boehringer IngelheimThe AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis | 2027-06-15 |
| NCT05860803Mayo ClinicBreathing Training and Exercise Capacity in Non-CFB | 2026-12-01 |
| NCT07135284Synchrony-Medical, LtdReal Life Evaluation of the LibAirty Airway Clearance System in Adults With Bronchiectasis (RELACS) | 2027-02 |
| NCT05846230Boehringer IngelheimClairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine | 2027-03-31 |
| NCT03839992Gelb, Arthur F., M.D.Detection of Unsuspected Small Airways Obstruction in Cystic Fibrosis | 2027-04-25 |
Add all 8 to your calendar (.ics) → With an account.
Among the 65 studies in Bronchiectasis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
ACT18018 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 study with 3 treatment groups. The purpose of this study was to evaluate efficacy, safety and tolerability with 2 dosing regimens of itepekimab compared with placebo in male and/or female participants with NCFB aged 18 years of age up to 85 years of age (inclusive).
Study details include:
The criteria were revised on the registry on Oct 7, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants were excluded from the study if any of the following criteria apply:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received itepekimab 300 mg Subcutaneous (SC) injection every 2 weeks (Q2W) for up to 52 weeks
Drug: Itepekimab (SAR440340)
Participants received itepekimab 300 mg SC injection Q4W with alternating placebo matched to itepekimab SC administration at the 2-week interval between active study drug for up to 52 weeks
Drug: Itepekimab (SAR440340) · Drug: Placebo
Participants received placebo matched to itepekimab subcutaneous (SC) injection Q2W for up to 52 weeks
Drug: Placebo
* Pharmaceutical form: solution for injection in pre-filled syringe * Route of administration: subcutaneous
Also known as: REGN3500
* Pharmaceutical form: solution for injection in pre-filled syringe * Route of administration: subcutaneous
Annualized Rate of Adjudicated Moderate or Severe Pulmonary Exacerbations (PEs) Over the Treatment Period
PEs were recorded by Investigator. Moderate PEs were defined as acute worsening of respiratory symptoms (\>=3 symptoms for \>=48 hours) requiring antibiotic treatment. Severe PEs were moderate PEs resulting in intravenous antibiotic treatment, hospitalization, observation \>24 hours in emergency department/urgent care, or death. Events separated by \<14 days were considered as single events. All PE events were adjudicated by an independent committee. For both moderate and severe events to be counted as 2 separate events, they were separated by at least 14 days between any course of antibiotics and/or systemic corticosteroids or 14 days between discharge and new admission in case of hospitalization (severe events only). Annualized rate: number of events divided by total observation duration and was estimated based on negative binomial regression.
Time frame: Baseline (Day 1) up to Week 24 to 52
Time to First Moderate or Severe Pulmonary Exacerbation Over the Treatment Period
Time to first moderate or severe PE was defined as the onset date of the first moderate or severe PE during the observation period (as per endpoint #1) minus (-) randomization date plus (+) 1. PEs were defined as an acute worsening of respiratory symptoms leading to a prescription in antibiotics (new, addition or change in) and/or systemic corticosteroids and were recorded by Investigator. For both moderate and severe events to be counted as 2 separate events, they must be separated by at least 14 days between any course of antibiotics or 14 days between discharge and new admission in case of hospitalization (severe events only).
Time frame: Baseline (Day 1) up to Week 24 to 52
Percentage of Participants Who Were Pulmonary Exacerbation Free Over the Treatment Period
PEs were defined as an acute worsening of respiratory symptoms leading to a prescription in antibiotics (new, addition or change in) and/or systemic corticosteroids and were recorded by Investigator. Percentage of participants who were moderate or severe PE free over the treatment period are reported. Moderate and severe PE as defined in endpoint #1. Percentages are rounded off to tenth decimal place.
Time frame: Baseline (Day 1) up to Week 24 to 52
Annualized Rate of Adjudicated Severe Pulmonary Exacerbations Over the Treatment Period
PEs were recorded by Investigator. Severe PEs were moderate PEs resulting in intravenous antibiotic treatment, hospitalization, observation \>24 hours in emergency department/urgent care, or death. All PE events were adjudicated by an independent committee. Annualized rate: number of events divided by total observation duration and was estimated based on negative binomial regression.
Time frame: Baseline (Day 1) up to Week 24 to 52
Percentage of Participants Who Were Severe Pulmonary Exacerbation Free Over the Treatment Period
PEs were defined as an acute worsening of respiratory symptoms) leading to a prescription in antibiotics (new, addition or change in) and/or systemic corticosteroids and were recorded by Investigator. Severe PE was defined as moderate PE described in endpoint #1 but resulting in intravenous antibiotic treatment, hospitalization, observation for \>24 hours in emergency department/urgent care facility or death. Percentage of participants who were severe PE free over the treatment period are reported. Percentages are rounded off to tenth decimal place.
Time frame: Baseline (Day 1) up to Week 24 to 52
Time to First Severe Pulmonary Exacerbation Over the Treatment Period
Time to first severe PE was defined as the onset date of the first severe PE during the observation period - randomization date + 1. PEs were defined as an acute worsening of respiratory symptoms leading to a prescription in antibiotics (new, addition or change in) and/or systemic corticosteroids and were recorded by Investigator. Severe PE was defined as moderate PE but resulting in intravenous antibiotic treatment, hospitalization, observation for \>24 hours in emergency department/urgent care facility or death.
Time frame: Baseline (Day 1) up to Week 24 to 52
Change From Baseline in Pre-bronchodilator (BD) Forced Expiratory Volume in One Second (FEV1) at Weeks 8 and 24
The FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Pre-BD spirometry was performed after a washout period of BD according to their action duration following the European Respiratory Society/American Thoracic Society 2019 guidance. Baseline was defined as the last available value before the first dose of double-blind study drug. Model-based average change from baseline to Weeks 8 and 24 is presented.
Time frame: Baseline (Day 1) and Weeks 8 and 24
Change From Baseline in Post-bronchodilator Forced Expiratory Volume in One Second at Weeks 8 and 24
The FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Post-BD spirometry was performed after 4 actuations of short-acting beta-agonist (albuterol, salbutamol) with post-BD reversibility performed at least 15 minutes following the last actuation. Baseline was defined as the last available value before the first dose of double-blind study drug. Model-based average change from baseline to Weeks 8 and 24 is presented.
Time frame: Baseline (Day 1) and Weeks 8 and 24
Median Days of New and/or Added (in Participants With Maintenance Antibiotic Use) Acute Antibiotics Used to Treat Pulmonary Exacerbation
PEs were defined as an acute worsening of respiratory symptoms leading to a prescription in antibiotics (new, addition or change in) and/or systemic corticosteroids and were recorded by Investigator. Systemic antibiotics used less than 60 days to treat a NCFB exacerbation were considered. Median number of days of new and/or added acute antibiotics used to treat PE in participants with maintenance antibiotic use is reported.
Time frame: Baseline (Day 1) up to Week 24 to 52
Change From Baseline in Quality-of-Life Questionnaire Bronchiectasis (QOL-B) Respiratory Symptoms Domain Score in Adult Participants at Week 24
QOL-B is self-administered patient reported outcome (PRO) that assesses symptoms, functioning and health-related QOL for participants with NCFB; contains 37 items in 8 domains (respiratory symptoms, physical functioning, role functioning, emotional functioning, social functioning, vitality, health perceptions and treatment burden). Respiratory Symptoms domain assesses respiratory symptom-related QOL;includes 9 questions (from 29 to 37 of QOL-B Questionnaire). Each of 37 items is scored from 1 to 4, and each of the 8 domains scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning/ better QOL.Positive change from baseline=improvement in symptoms. Baseline:last available value before first dose of double-blind study drug. Model-based average change from baseline to Week 24 is presented.
Time frame: Baseline (Day 1) and Week 24
Change From Baseline in Saint Georges Respiratory Questionnaire (SGRQ) Total Score at Week 24
SGRQ is a 50-item PRO instrument to measure health status of participants with airflow obstruction diseases. Questionnaire is divided into 2 parts: part 1 consists of 8 items pertaining to severity of respiratory symptoms in preceding 4 weeks; part 2 consists of 42 items related to daily activity and psychosocial impacts of individual's respiratory condition. Scores by dimension are calculated for 3 domains: symptoms, activity and impacts (psychosocial). Total score is calculated by summing all positive responses in questionnaire and expressing result as percentage of total weight for questionnaire; ranges 0 (best possible health status) to 100 (worst possible health status); lower score indicates better QOL. Baseline was defined as the last available value before first dose of double-blind study drug. Model-based average change from baseline to Week 24 is presented.
Time frame: Baseline (Day 1) and Week 24
Percentage of Participants With a Decrease From Baseline of at Least 4 Points in Saint Georges Respiratory Questionnaire Total Score at Week 24
SGRQ is a 50-item PRO instrument to measure health status of participants with airflow obstruction diseases. Questionnaire is divided into 2 parts: part 1 consists of 8 items pertaining to severity of respiratory symptoms in preceding 4 weeks; part 2 consists of 42 items related to daily activity and psychosocial impacts of individual's respiratory condition. Scores by dimension are calculated for 3 domains: symptoms, activity and impacts (psychosocial). Total score is calculated by summing all positive responses in questionnaire and expressing result as percentage of total weight for questionnaire; ranges 0 (best possible health status) to 100 (worst possible health status); lower scores indicate better QOL. Baseline was defined as the last available value before first dose of double-blind study drug. Percentages are rounded off to tenth decimal place.
Time frame: Baseline (Day 1) and Week 24
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-Emergent AEs of Special Interest (TEAESIs), Treatment-emergent Serious Adverse Events (TESAEs) and TEAEs Leading to Permanent Study Drug Discontinuation
AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. AESI was any AE (serious or non-serious) of scientific and medical concern specific to Sponsor's product or program, for which ongoing monitoring and immediate notification by Investigator to Sponsor was required. SAE was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were AEs that developed, worsened or became serious during the TE period.
Time frame: From first dose of study drug (Day 1) to a maximum of 72 weeks
Serum Concentrations of Itepekimab
Blood samples were collected at specified timepoints to obtain serum concentrations of itepekimab.
Time frame: Baseline (Day 1) and Weeks 4, 8, 24, 52, end of treatment (EOT) (Weeks 24-52) and end of study (EOS) (up to Week 72)
Number of Participants With Treatment-emergent Anti-drug Antibodies (ADA) Response Against Itepekimab
Blood samples were collected to evaluate antibodies to itepekimab. Treatment-emergent response was defined as a positive response in the ADA assay post first dose when baseline results were negative or missing. Number of participants with treatment-emergent ADAs against itepekimab is presented.
Time frame: From first dose of study drug (Day 1) to a maximum of 72 weeks
This study was conducted at 117 sites in 20 countries. 386 participants were screened from 20-Feb-2024 to 07-Mar-2025 of which 72 were screen failures due to not meeting eligibility criteria. A total of 314 participants with non-cystic fibrosis bronchiectasis (NCFB) were randomized in this study in a 1:1:1 ratio to either receive placebo matched to itepekimab or itepekimab (once every 2 weeks \[Q2W\] or once every 4 weeks \[Q4W\]).
| Milestone | Placebo | Itepekimab 300 mg Q4W | Itepekimab 300 mg Q2W |
|---|---|---|---|
| Started | 102 | 104 | 108 |
| Randomized and treated | 102 | 103 | 107 |
| Completed | 84 | 90 | 93 |
| Not completed | 18 | 14 | 15 |
| Withdrew: Adverse event | 4 | 2 | 2 |
| Withdrew: Non-compliance with study schedule | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 13 | 6 | 11 |
| Withdrew: Other | 1 | 4 | 1 |
| Withdrew: Randomized but not treated | 0 | 1 | 1 |
PEs were recorded by Investigator. Moderate PEs were defined as acute worsening of respiratory symptoms (\>=3 symptoms for \>=48 hours) requiring antibiotic treatment. Severe PEs were moderate PEs resulting in intravenous antibiotic treatment, hospitalization, observation \>24 hours in emergency department/urgent care, or death. Events separated by \<14 days were considered as single events. All PE events were adjudicated by an independent committee. For both moderate and severe events to be counted as 2 separate events, they were separated by at least 14 days between any course of antibiotics and/or systemic corticosteroids or 14 days between discharge and new admission in case of hospitalization (severe events only). Annualized rate: number of events divided by total observation duration and was estimated based on negative binomial regression.
| events per participant year | Placebo | Itepekimab 300 mg Q4W | Itepekimab 300 mg Q2W |
|---|---|---|---|
| Annualized Rate of Adjudicated Moderate or Severe Pulmonary Exacerbations (PEs) Over the Treatment Period | 1.238 (0.898 to 1.708) | 1.053 (0.767 to 1.447) | 1.029 (0.750 to 1.412) |
Time to first moderate or severe PE was defined as the onset date of the first moderate or severe PE during the observation period (as per endpoint #1) minus (-) randomization date plus (+) 1. PEs were defined as an acute worsening of respiratory symptoms leading to a prescription in antibiotics (new, addition or change in) and/or systemic corticosteroids and were recorded by Investigator. For both moderate and severe events to be counted as 2 separate events, they must be separated by at least 14 days between any course of antibiotics or 14 days between discharge and new admission in case of hospitalization (severe events only).
| weeks | Placebo | Itepekimab 300 mg Q4W | Itepekimab 300 mg Q2W |
|---|---|---|---|
| Time to First Moderate or Severe Pulmonary Exacerbation Over the Treatment Period | 22.0 (17.00 to 33.00) | 38.1 (27.86 to NA) | 42.0 (34.86 to NA) |
PEs were defined as an acute worsening of respiratory symptoms leading to a prescription in antibiotics (new, addition or change in) and/or systemic corticosteroids and were recorded by Investigator. Percentage of participants who were moderate or severe PE free over the treatment period are reported. Moderate and severe PE as defined in endpoint #1. Percentages are rounded off to tenth decimal place.
| percentage of participants | Placebo | Itepekimab 300 mg Q4W | Itepekimab 300 mg Q2W |
|---|---|---|---|
| Percentage of Participants Who Were Pulmonary Exacerbation Free Over the Treatment Period | 41.2 | 50.0 | 53.7 |
PEs were recorded by Investigator. Severe PEs were moderate PEs resulting in intravenous antibiotic treatment, hospitalization, observation \>24 hours in emergency department/urgent care, or death. All PE events were adjudicated by an independent committee. Annualized rate: number of events divided by total observation duration and was estimated based on negative binomial regression.
| events per participant year | Placebo | Itepekimab 300 mg Q4W | Itepekimab 300 mg Q2W |
|---|---|---|---|
| Annualized Rate of Adjudicated Severe Pulmonary Exacerbations Over the Treatment Period | 0.270 (0.131 to 0.556) | 0.108 (0.047 to 0.247) | 0.216 (0.105 to 0.444) |
PEs were defined as an acute worsening of respiratory symptoms) leading to a prescription in antibiotics (new, addition or change in) and/or systemic corticosteroids and were recorded by Investigator. Severe PE was defined as moderate PE described in endpoint #1 but resulting in intravenous antibiotic treatment, hospitalization, observation for \>24 hours in emergency department/urgent care facility or death. Percentage of participants who were severe PE free over the treatment period are reported. Percentages are rounded off to tenth decimal place.
| percentage of participants | Placebo | Itepekimab 300 mg Q4W | Itepekimab 300 mg Q2W |
|---|---|---|---|
| Percentage of Participants Who Were Severe Pulmonary Exacerbation Free Over the Treatment Period | 83.3 | 94.2 | 87.0 |
Time to first severe PE was defined as the onset date of the first severe PE during the observation period - randomization date + 1. PEs were defined as an acute worsening of respiratory symptoms leading to a prescription in antibiotics (new, addition or change in) and/or systemic corticosteroids and were recorded by Investigator. Severe PE was defined as moderate PE but resulting in intravenous antibiotic treatment, hospitalization, observation for \>24 hours in emergency department/urgent care facility or death.
| weeks | Placebo | Itepekimab 300 mg Q4W | Itepekimab 300 mg Q2W |
|---|---|---|---|
| Time to First Severe Pulmonary Exacerbation Over the Treatment Period | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
The FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Pre-BD spirometry was performed after a washout period of BD according to their action duration following the European Respiratory Society/American Thoracic Society 2019 guidance. Baseline was defined as the last available value before the first dose of double-blind study drug. Model-based average change from baseline to Weeks 8 and 24 is presented.
| liters | Placebo | Itepekimab 300 mg Q4W | Itepekimab 300 mg Q2W |
|---|---|---|---|
| Week 8 | -0.03 ± 0.02 | 0.01 ± 0.02 | -0.02 ± 0.02 |
| Week 24 | -0.01 ± 0.03 | 0.00 ± 0.03 | -0.04 ± 0.03 |
The FEV1 was the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometer. Post-BD spirometry was performed after 4 actuations of short-acting beta-agonist (albuterol, salbutamol) with post-BD reversibility performed at least 15 minutes following the last actuation. Baseline was defined as the last available value before the first dose of double-blind study drug. Model-based average change from baseline to Weeks 8 and 24 is presented.
| liters | Placebo | Itepekimab 300 mg Q4W | Itepekimab 300 mg Q2W |
|---|---|---|---|
| Week 8 | -0.00 ± 0.02 | 0.03 ± 0.02 | 0.01 ± 0.02 |
| Week 24 | 0.00 ± 0.02 | 0.02 ± 0.02 | -0.00 ± 0.02 |
PEs were defined as an acute worsening of respiratory symptoms leading to a prescription in antibiotics (new, addition or change in) and/or systemic corticosteroids and were recorded by Investigator. Systemic antibiotics used less than 60 days to treat a NCFB exacerbation were considered. Median number of days of new and/or added acute antibiotics used to treat PE in participants with maintenance antibiotic use is reported.
| days | Placebo | Itepekimab 300 mg Q4W | Itepekimab 300 mg Q2W |
|---|---|---|---|
| Median Days of New and/or Added (in Participants With Maintenance Antibiotic Use) Acute Antibiotics Used to Treat Pulmonary Exacerbation | 18.00 (3.0 to 56.0) | 12.50 (4.0 to 40.0) | 14.50 (3.0 to 52.0) |
QOL-B is self-administered patient reported outcome (PRO) that assesses symptoms, functioning and health-related QOL for participants with NCFB; contains 37 items in 8 domains (respiratory symptoms, physical functioning, role functioning, emotional functioning, social functioning, vitality, health perceptions and treatment burden). Respiratory Symptoms domain assesses respiratory symptom-related QOL;includes 9 questions (from 29 to 37 of QOL-B Questionnaire). Each of 37 items is scored from 1 to 4, and each of the 8 domains scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning/ better QOL.Positive change from baseline=improvement in symptoms. Baseline:last available value before first dose of double-blind study drug. Model-based average change from baseline to Week 24 is presented.
| score on a scale | Placebo | Itepekimab 300 mg Q4W | Itepekimab 300 mg Q2W |
|---|---|---|---|
| Change From Baseline in Quality-of-Life Questionnaire Bronchiectasis (QOL-B) Respiratory Symptoms Domain Score in Adult Participants at Week 24 | 4.42 ± 2.54 | 6.49 ± 2.39 | 5.84 ± 2.40 |
SGRQ is a 50-item PRO instrument to measure health status of participants with airflow obstruction diseases. Questionnaire is divided into 2 parts: part 1 consists of 8 items pertaining to severity of respiratory symptoms in preceding 4 weeks; part 2 consists of 42 items related to daily activity and psychosocial impacts of individual's respiratory condition. Scores by dimension are calculated for 3 domains: symptoms, activity and impacts (psychosocial). Total score is calculated by summing all positive responses in questionnaire and expressing result as percentage of total weight for questionnaire; ranges 0 (best possible health status) to 100 (worst possible health status); lower score indicates better QOL. Baseline was defined as the last available value before first dose of double-blind study drug. Model-based average change from baseline to Week 24 is presented.
| score on a scale | Placebo | Itepekimab 300 mg Q4W | Itepekimab 300 mg Q2W |
|---|---|---|---|
| Change From Baseline in Saint Georges Respiratory Questionnaire (SGRQ) Total Score at Week 24 | -2.40 ± 2.20 | -3.72 ± 2.07 | -5.27 ± 2.09 |
SGRQ is a 50-item PRO instrument to measure health status of participants with airflow obstruction diseases. Questionnaire is divided into 2 parts: part 1 consists of 8 items pertaining to severity of respiratory symptoms in preceding 4 weeks; part 2 consists of 42 items related to daily activity and psychosocial impacts of individual's respiratory condition. Scores by dimension are calculated for 3 domains: symptoms, activity and impacts (psychosocial). Total score is calculated by summing all positive responses in questionnaire and expressing result as percentage of total weight for questionnaire; ranges 0 (best possible health status) to 100 (worst possible health status); lower scores indicate better QOL. Baseline was defined as the last available value before first dose of double-blind study drug. Percentages are rounded off to tenth decimal place.
| percentage of participants | Placebo | Itepekimab 300 mg Q4W | Itepekimab 300 mg Q2W |
|---|---|---|---|
| Percentage of Participants With a Decrease From Baseline of at Least 4 Points in Saint Georges Respiratory Questionnaire Total Score at Week 24 | 37.2 | 41.6 | 57.4 |
AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. AESI was any AE (serious or non-serious) of scientific and medical concern specific to Sponsor's product or program, for which ongoing monitoring and immediate notification by Investigator to Sponsor was required. SAE was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were AEs that developed, worsened or became serious during the TE period.
| Participants | Placebo | Itepekimab 300 mg Q4W | Itepekimab 300 mg Q2W |
|---|---|---|---|
| TEAEs | 84 | 84 | 88 |
| TEAESIs | 32 | 32 | 23 |
| TESAEs | 24 | 20 | 16 |
| TEAEs Leading to Permanent Study Drug Discontinuation | 2 | 2 | 2 |
Blood samples were collected at specified timepoints to obtain serum concentrations of itepekimab.
| nanogram per milliliter | Itepekimab 300 mg Q4W | Itepekimab 300 mg Q2W |
|---|---|---|
| Baseline (Day 1) | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Week 4 | 15851.09 ± 5329.71 | 35653.40 ± 11140.03 |
| Week 8 | 22755.35 ± 8591.23 | 50656.86 ± 17264.57 |
| Week 24 | 31375.21 ± 14197.76 | 67857.29 ± 26838.42 |
| Week 52 | 31874.79 ± 12665.57 | 63649.74 ± 28768.37 |
| EOT | 32840.10 ± 16186.17 | 61647.04 ± 26539.85 |
| EOS | 3496.34 ± 9047.41 | 3783.34 ± 7095.42 |
Blood samples were collected to evaluate antibodies to itepekimab. Treatment-emergent response was defined as a positive response in the ADA assay post first dose when baseline results were negative or missing. Number of participants with treatment-emergent ADAs against itepekimab is presented.
| Participants | Itepekimab 300 mg Q4W | Itepekimab 300 mg Q2W |
|---|---|---|
| Number of Participants With Treatment-emergent Anti-drug Antibodies (ADA) Response Against Itepekimab | 2 | 2 |
Collected over AEs were collected from first dose of study drug (Day 1) to a maximum of 72 weeks. All-cause mortality (death) was assessed from Day 1 up to end of follow-up for each participant, approximately 101 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 3/102 (2.9%) | 24/102 (23.5%) | 57/102 (55.9%) |
| Itepekimab 300 mg Q4W | 1/103 (1%) | 20/103 (19.4%) | 48/103 (46.6%) |
| Itepekimab 300 mg Q2W | 1/107 (0.9%) | 16/107 (15%) | 60/107 (56.1%) |
| Event | Placebo | Itepekimab 300 mg Q4W | Itepekimab 300 mg Q2W |
|---|---|---|---|
| BronchiectasisRespiratory, thoracic and mediastinal disorders | 9/102 | 5/103 | 9/107 |
| PneumoniaInfections and infestations | 5/102 | 5/103 | 1/107 |
| InfluenzaInfections and infestations | 2/102 | 0/103 | 0/107 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 2/102 | 2/103 | 1/107 |
| Breast CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/102 | 2/103 | 0/107 |
| Femur FractureInjury, poisoning and procedural complications | 1/102 | 2/103 | 1/107 |
| Lower Respiratory Tract InfectionInfections and infestations | 1/102 | 0/103 | 2/107 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 0/102 | 0/103 | 2/107 |
| Pneumonia AspirationInfections and infestations | 1/102 | 0/103 | 0/107 |
| Pneumonia KlebsiellaInfections and infestations | 1/102 | 0/103 | 0/107 |
| Event | Placebo | Itepekimab 300 mg Q4W | Itepekimab 300 mg Q2W |
|---|---|---|---|
| BronchiectasisRespiratory, thoracic and mediastinal disorders | 30/102 | 29/103 | 26/107 |
| Upper Respiratory Tract InfectionInfections and infestations | 12/102 | 7/103 | 13/107 |
| NasopharyngitisInfections and infestations | 9/102 | 6/103 | 12/107 |
| HeadacheNervous system disorders | 5/102 | 1/103 | 9/107 |
| InfluenzaInfections and infestations | 7/102 | 1/103 | 4/107 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 7/102 | 5/103 | 4/107 |
| Iron Deficiency AnaemiaBlood and lymphatic system disorders | 1/102 | 7/103 | 1/107 |
| SinusitisInfections and infestations | 6/102 | 4/103 | 3/107 |
| PneumoniaInfections and infestations | 1/102 | 6/103 | 4/107 |
| Injection Site ErythemaGeneral disorders | 1/102 | 5/103 | 6/107 |
The randomized population included all participants from screened population who had been allocated to a randomized study drug by interactive response technology regardless of whether the study drug was received.
| Age, Continuous(years) | Placebo | Itepekimab 300 mg Q4W | Itepekimab 300 mg Q2W | Total |
|---|---|---|---|---|
| Mean | 61.42 ± 13.64 | 61.58 ± 15.01 | 60.22 ± 14.59 | 61.06 ± 14.40 |
| Sex: Female, Male(Participants) | Placebo | Itepekimab 300 mg Q4W | Itepekimab 300 mg Q2W | Total |
|---|---|---|---|---|
| Female | 73 | 69 | 71 | 213 |
| Male | 29 | 35 | 37 | 101 |
| Race (NIH/OMB)(Participants) | Placebo | Itepekimab 300 mg Q4W | Itepekimab 300 mg Q2W | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 17 | 19 | 20 | 56 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| Black or African American | 0 | 2 | 0 | 2 |
| White | 84 | 79 | 82 | 245 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 4 | 5 | 10 |
Showing the first 100 of 117 sites across 20 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Feb 2024 to primary completion in Sep 2025, 18 months.
Results were first posted in Oct 2026, 1 year after primary completion.
Of 24 phase 2 interventional studies under Bronchiectasis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 32. This study's 18 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Itepekimab